AWD-12-281 (inhaled) (elbion/GlaxoSmithKline).

Hans‐Juergen Gutke,J. Guse,Moussa Khobzaoui,Thejavathi Renukappa-Gutke,M. Burnet
2005-11-01
Abstract:elbion (formerly ASTA Medica) and GlaxoSmithKline are developing an inhaled formulation of AWD-12-281 for the potential treatment of chronic obstructive pulmonary disease (COPD). By May 2005, phase II trials of this 5-hydroxyindole PDE4 inhibitor for COPD were ongoing.
What problem does this paper attempt to address?